Mandate

Vinge advises Jays Group on a rights issue

The board of directors of Jays Group AB (publ) has resolved pursuant to authorization granted at an annual general meeting to perform a new issue of shares amounting to approximately MSEK 41 subject to pre-emption rights for the company’s existing shareholders.

Pursuant to subscription undertakings and guarantee obligations, the new issue of shares is secured to approximately MSEK 36.9, corresponding to 90% of the total proceeds of the new issue of shares. The offer is performed in order to further strengthen the company’s trademark and product portfolio and strengthen the balance sheet prior to future acquisition financing. The prospectus is planned to be published on 24 May and the subscription period commences on 27 May.

Vinge’s team consists of responsible partner Anders Strid together with Frida Bergqvist (project manager), Jenny Sandlund, Victor Ericsson (tax) and Camilla Andersson (company assistant).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026